By Route of Administration

Intravenous (IV Infusion, Clinic-Administered) Market Analysis

Cross-industry research covering Intravenous (IV Infusion, Clinic-Administered) across 1 market reportspanning Pharmaceuticals.

1 Reports

1 Industries

Reports Covering Intravenous (IV Infusion, Clinic-Administered)

Dysautonomia Treatment Drugs Market to Reach USD 8.4 Billion by 2033 at 7.2% CAGR

Pharmaceuticals·Market: USD 4.8 Billion (2025)·CAGR: 7.2%

IV saline infusion for POTS and IVIG for autoimmune autonomic disorders are administered in ambulatory infusion centers billed under Medicare Part B, generating a structurally higher per-encounter revenue than Part D oral prescriptions; this route is growing disproportionately with post-COVID autonomic case volume.

16%

Market Share

9.8%

Segment CAGR

Explore More Segments

Browse all market segments across our research coverage.

View all segments